Repligen Corporation logo

Repligen Corporation (RGEN)

Market Open
1 Sep, 18:41
NASDAQ (NGS) NASDAQ (NGS)
$
169. 00
-11.98
-6.6195%
$
10.21B Market Cap
212.35 P/E Ratio
- Div Yield
693,989 Volume
1.46 Eps
$ 180.98
Previous Close
Add Transaction
Day Range
168.71 182.57
Year Range
100.99 188.73
Want to track RGEN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

RGEN trading today lower at $169, a decrease of -6.6195% from yesterday's close, completing a monthly increase of 18.9638% or $26.94. Over the past 12 months, RGEN stock gained 3.345%.
RGEN is not paying dividends to its shareholders.
The last earnings report, released on May 05, 2026, missed the consensus estimates by -0.4474%. On average, the company has fell short of earnings expectations by -0.2804%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

RGEN Chart

People also search for

Shopify Inc.
$ 139.86
-5.096%
STX
Seagate Technology Holdings plc
$ 814.17
-1.7154%
ADI
Analog Devices, Inc.
$ 353.17
-2.4769%
QUALCOMM Incorporated
$ 165.64
-2.839%
WDC
Western Digital Corporation
$ 451.74
+0.2641%
Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?

Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Zacks | 5 days ago
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

Zacks | 5 days ago
Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade

Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade

The consensus price target hints at a 25.7% upside potential for Repligen (RGEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks | 1 month ago

Repligen Corporation Investors

Name Quantity Cost Value Profit ($) Gain (%)
Curtis Ellergodt
Curtis Ellergodt Rothschild Investment LLC
466 $82,861.39 $74,299.04 -$8,562.35 -10.33%
BZ
Brandon Zatopek Commonwealth Equity Services LLC
18,056 $2.46M $2.96M $495,818.22 20.13%
ABB
Alexander Bjornager Bonde Danske Bank A/S
100 $16,386 $16,390 $4 0.02%
JD
Jim Dushek HARBOUR INVESTMENTS Inc.
12 $1,654.66 $1,977.24 $322.58 19.5%
Wallace Weitz
Wallace Weitz Weitz Investment Management Inc.
40,800 $5.09M $6.72M $1.63M 32.02%

Repligen Corporation Analysts

Name Quantity Cost Value Profit ($) Gain (%)
RW
Robert Wasserman Benchmark
116.86 $16,340.34 $16,984.23 $643.89 3.94%

Repligen Corporation (RGEN) FAQ

What is the stock price today?

The current price is $169.00.

On which exchange is it traded?

Repligen Corporation is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is RGEN.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 10.21B.

Has Repligen Corporation ever had a stock split?

No, there has never been a stock split.

Repligen Corporation Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
Olivier Loeillot CEO
NASDAQ (NGS) Exchange
759916109 CUSIP
US Country
2,000 Employees
- Last Dividend
- Last Split
26 Mar 1990 IPO Date

Overview

Repligen Corporation is an innovative force in the biotechnological industry, primarily focusing on the development and commercialization of bioprocessing technologies and systems that play a crucial role in biological drug manufacturing. With a global reach that extends across North America, Europe, the Asia Pacific, and additional international markets, Repligen stands at the forefront of facilitating the production of biological drugs. The company, incorporated in 1981 and based in Waltham, Massachusetts, has established itself as a pivotal contributor to the biopharmaceutical and diagnostics sectors by offering a robust portfolio of products designed to enhance the efficiency and productivity of drug manufacturing processes. Through strategic collaboration agreements, such as with Navigo Proteins GmbH, Repligen continues to expand its technological arsenal, ensuring it remains synonymous with innovation and quality in the bioprocessing industry.

Products and Services

  • Protein A Ligands and Cell Culture Growth Factor Products: They serve as the binding components of Protein A affinity chromatography resins, crucial for purifying biologics, alongside products designed to enhance cell culture growth, thereby increasing the yield of bioprocesses.
  • Chromatography Products: This encompasses OPUS pre-packed chromatography columns for biologics purification, alongside smaller-scale columns used in process development, viral clearance, and process validation studies, reinforcing the versatility and efficiency of bioprocessing workflows.
  • ELISA Test Kits and CaptivA Resins: These are essential for the detection and quantification of various biological agents, with chromatography resins under the CaptivA brand further supporting the purification stages of drug manufacturing.
  • Filtration Products: The line includes XCell Alternating Tangential Flow systems for upstream perfusion and cell culture, TangenX cassettes, and KrosFlo systems for downstream processing like drug concentration and buffer exchange, alongside Spectra/Por dialysis products and ProConnex flow paths, showcasing a comprehensive range of solutions for biologic drug filtration needs.
  • Process Analytics Products: With slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands, Repligen offers innovative solutions for process analytics, enabling more efficient and accurate monitoring and optimization of bioprocessing parameters.

Contact Information

Address: Building 1
Phone: 781 250 0111